我要投票 白敬宇在医疗用品行业中的票数:12
· 外 推 电 报 ·
2024-11-22 20:09:32 星期五

【白敬宇是哪个国家的品牌?】

白敬宇是什么牌子?「白敬宇」是 南京白敬宇制药有限责任公司 旗下著名品牌。该品牌发源于江苏,由创始人陈在1991-07-12期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

南京白敬宇制药是一家生产化学原料药及制剂药的综合性制药公司,首批“中华老字号”和江苏省高新技术企业。公司前身“白敬宇眼药厂”1937年在南京成立,“白敬宇”商标于1939年注册,是中国为数极少的民国时期药品注册商标之一,2011年被国家工商总局认定为“中国驰名商标”。公司现有员工近800人,近三年累计产销和利税分别为12.67亿元和1.16亿元,2012年在岗员工人均可支配收入6.22万元。

公司原料药和制剂药生产基地分别位于六合化学工业园区和新港经济技术开发区,两个厂区绿树成荫,均为园区的“园林式工厂”,在2010-2011年先后通过了ISO9001质量体系认证、ISO14001环境管理体系认证以及ISO18001职业健康安全管理体系的认证,在同类企业中处于领先地位。

公司现有注册产品120个,其中原料药27个,制剂药93个。制剂药有片剂、膏剂、胶囊剂、散剂、酊剂、混悬液剂、凝胶剂等15个剂型,主要产品有心脑血管、祛痰镇咳、抗感染、维生素类、眼用膏剂等系列品种,有26个产品进入国家基本药物目录。主要剂型的年最大产量为:片剂80亿片,激素药20亿片,酊水100万升,膏剂6500万支,胶囊剂6.5亿粒,混悬剂45万升、洗剂5万升、散剂9000万包。公司另有24个品规的制剂药产品在12个国家取得了药品注册证书,产品销售到38个国家和地区。公司原料药常年生产盐酸左旋咪唑、酮康唑、氯霉素及酮酸钙等产品,年生产能力大于1000吨。原料药3个主要品种已在欧洲、美国、日本、俄罗斯等国注册销售。

公司的“国际合作”理念决定了公司对原料生产区的环保治理具有超前意识,按照国际惯例,客户在接受产品前必须对企业进行严格的全面质量审计,其中“人的安全和环境保护”是审计的重要项目,因此,供应商审计是公司能够不断进步的动力。2006年至今,原料药厂区共接受国外供应商审计20余次,其中有美国通用、比利时杨森、德国拜耳、西班牙因杜肯等国际性大公司,公司现已成为上述公司的产品供应商。

公司是南京市药品出口产量最大的企业,尤其是制剂药出口更是领先,自营出口1千万美元,出口供货值1亿元人民币。公司以“做好产品、卖好产品”为宗旨,致力于实业拓展。公司的目标是:到2014年,产品制造水平要达到国内一流、国际中等以上标准,以满足不同市场的客户需要,确保企业可持续发展。

英文翻译:Nanjing Baijingyu Pharmaceutical Co., Ltd. is a comprehensive pharmaceutical company that produces chemical raw materials and pharmaceutical preparations. It is one of the first batch of "Chinese time-honored brands" and high-tech enterprises in Jiangsu Province. The company's predecessor, Bai Jingyu eye pharmaceutical factory, was established in Nanjing in 1937. The trademark of Bai Jingyu was registered in 1939. It is one of the few drug registered trademarks in the Republic of China. In 2011, it was recognized as "China's famous trademark" by the State Administration of industry and Commerce. The company has nearly 800 employees. In the past three years, the cumulative production and sales and profits and taxes are RMB 1.267 billion and RMB 116 million respectively. In 2012, the average disposable income of on-the-job employees is RMB 62200. The company's API and pharmaceutical production bases are respectively located in Liuhe chemical industry park and Xingang economic and Technological Development Zone. Both of the two plants are "garden type factories" in the park. From 2010 to 2011, they have passed ISO9001 quality system certification, ISO14001 environmental management system certification and ISO18001 occupational health and safety management system certification, and are in the leading position among similar enterprises First place. The company has 120 registered products, including 27 APIs and 93 pharmaceutical preparations. Preparations include tablets, ointments, capsules, powder, tincture, suspension, gel and other 15 formulations. The main products are cardiovascular, expectorant, antitussive, anti infective, vitamin, eye paste and other varieties. 26 products have entered the national essential drug list. The annual maximum production of main dosage forms is: 8 billion tablets, 2 billion hormone drugs, 1 million liters tincture water, 65 million plasters, 650 million capsules, 450000 liters suspension, 50000 liters lotion and 90 million packages powder. Another 24 pharmaceutical products of the company have obtained drug registration certificates in 12 countries, and the products have been sold to 38 countries and regions. The company's APIs produce levamisole hydrochloride, ketoconazole, chloramphenicol, calcium ketoacid and other products throughout the year, with an annual production capacity of more than 1000 tons. Three main varieties of APIs have been registered and sold in Europe, the United States, Japan, Russia and other countries. The company's concept of "international cooperation" determines that the company has an advanced awareness of environmental protection in the raw material production area. According to international practice, customers must conduct a strict overall quality audit on the enterprise before accepting products. Among them, "human safety and environmental protection" is an important audit project. Therefore, supplier audit is the driving force for the company to make continuous progress. Since 2006, the API plant area has been audited by foreign suppliers for more than 20 times, among which there are international large companies such as general motors of the United States, Janssen of Belgium, Bayer of Germany, induken of Spain, etc. the company has become the product supplier of the above companies. The company is the largest pharmaceutical export enterprise in Nanjing, especially the leading pharmaceutical export, with self export of US $10 million and export supply value of RMB 100 million. With the tenet of "do well in products and sell well in products", the company is committed to industrial development. The company's goal is: by 2014, the product manufacturing level should reach the domestic first-class, international medium-sized and above standards, so as to meet the needs of customers in different markets and ensure the sustainable development of the enterprise.

本文链接: https://www.waitui.com/brand/ba0510fe3.html 联系电话:02586504321

千城特选小程序码

7×24h 快讯

梅花生物:拟105亿日元收购协和发酵旗下的食品氨基酸等业务及资产

36氪获悉,梅花生物发布公告,全资子公司新加坡公司拟以105亿日元(折合人民币约5亿元左右)收购Kirin Holdings Company, Limited(简称“麒麟控股”,东京证券交易所上市公司,股票代码2503.T)的全资子公司Kyowa Hakko Bio Co., Ltd.(协和发酵株式会社,简称“协和发酵”)旗下的食品氨基酸、医药氨基酸、母乳低聚糖业务及资产。

10分钟前

三鑫医疗:获得医疗器械注册证

36氪获悉,三鑫医疗发布公告,公司及控股子公司宁波菲拉尔医疗用品有限公司于近日分别获得了国家药监局颁发的血液透析滤过器、一次性使用右心吸引头《医疗器械注册证》。

10分钟前

上海电影:拟收购上影元19%股权

36氪获悉,上海电影发布公告,公司拟以现金形式收购控股股东上影集团、上美影分别持有的公司控股子公司上影元(上海)文化科技发展有限公司(简称上影元)14%、5%股权,对应转让价格预计分别为不超过4902.8万元、1751万元。本次交易完成后,上影元股权结构为公司持股70%,上美影持股30%。

10分钟前

英国监管机构拟调查苹果与谷歌的移动生态系统活动

英国竞争与市场管理局(CMA)11月22日发布声明称,正考虑根据明年生效的数字市场竞争新规优先调查苹果和谷歌的移动生态系统活动。CMA独立调查小组的研究发现,苹果和谷歌在移动生态系统形成了实际上的“双头垄断”,包括移动设备上的操作系统、应用商店和网络浏览器。该小组认为,苹果的政策阻碍了移动浏览器的创新。CMA表示,将在当地时间12月13日前邀请公众就上述临时调查结果发表评论,预计将在明年3月做出最终决定。(界面)

10分钟前

​中晟高科:拟4.57亿元出售中晟新材100%股权

36氪获悉,中晟高科发布公告,公司通过在产权交易中心公开挂牌转让的方式,出售持有的中晟新材100%股权。在首次挂牌信息发布期限内征集到意向受让方泷祥投资,本次标的资产交易对方确定为泷祥投资,交易对价确定为4.57亿元。

10分钟前

本页详细列出关于白敬宇的品牌信息,含品牌所属公司介绍,白敬宇所处行业的品牌地位及优势。
咨询